Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Medtronic
Mallinckrodt
Baxter
Johnson and Johnson

Last Updated: February 24, 2020

DrugPatentWatch Database Preview

Claims for Patent: 7,091,333

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,091,333
Title:Antisense IAP nucleobase oligomers and uses thereof
Abstract: The present invention features nucleobase oligomers that hybridize to IAP polynucleotides, and methods for using them to enhance apoptosis and treat proliferative diseases.
Inventor(s): LaCasse; Eric (Ottawa, CA), McManus; Daniel (Ottawa, CA), Durkin; Jon P. (Ottawa, CA)
Assignee: Aegera Therapeutics, Inc. (Verdun, CA)
Application Number:10/400,382
Patent Claims:1. A nucleobase oligomer consisting of SEQ ID NO: 143.

2. A nucleobase oligomer of up to 30 nucleobases in length, said nucleobase oligomer comprising SEQ ID NO: 143, wherein said nucleobase oligomer is an oligonucleotide that comprises at least one modified linkage.

3. The nucleobase oligomer of claim 2, wherein said modified linkage is selected from the group consisting of phosphorothioate, methylphosphonate, phosphotriester, phosphorodithioate, and phosphoselenate linkages.

4. A nucleobase oligomer of up to 30 nucleobases in length, said nucleobase oligomer comprising SEQ ID NO: 143, wherein said nucleobase oligomer comprises at least one modified sugar moiety.

5. The nucleobase oligomer of claim 4, wherein said modified sugar moiety is a 2'-O-methyl group or a 2'-O-methoxyethyl group.

6. A nucleobase oligomer of up to 30 nucleobases in length, said nucleobase oligomer comprising SEQ ID NO: 143, wherein said nucleobase oligomer comprises at least one modified nucleobase.

7. The nucleobase oligomer of claim 6, wherein said modified nucleobase is 5-methyl cytosine.

8. A nucleobase oligomer of up to 30 nucleobases in length, said nucleobase oligomer comprising SEQ ID NO: 143, wherein said nucleobase oligomer is a chimeric nucleobase oligomer.

9. The nucleobase oligomer of claim 8, wherein said nucleobase oligomer comprises DNA residues linked together by phosphorothioate linkages, said DNA residues flanked on each side by at least one 2'-O-methyl or 2'-O-methoxyethyl RNA residue.

10. The nucleobase oligomer of claim 9, wherein said DNA residues are flanked on each side by at least three 2'-O-methyl or 2'-O-methoxyethyl RNA residues.

11. The nucleobase oligomer of claim 10, wherein said DNA residues are flanked on each side by four 2'-O-methyl or 2'-O-methoxyethyl RNA residues.

12. The nucleobase oligomer of claim 9, wherein said RNA residues are linked together by phosphorothioate linkages, and said RNA residues are linked to said DNA residues by phosphorothioate linkages.

13. The nucleobase oligomer of claim 8, wherein said nucleobase oligomer comprises DNA residues linked together by phosphodiester linkages, said DNA residues flanked on each side by at least two 2'-O-methyl or 2'-O-methoxyethyl RNA residues linked together by phosphorothioate linkages.

14. The nucleobase oligomer of claim 13, wherein said DNA residues are flanked on each side by at least three 2'-O-methyl or 2'-O-methoxyethyl RNA residues.

15. A nucleobase oligomer comprising eleven DNA residues flanked on each side by four 2'-O-methyl RNA residues, said nucleobase oligomer consisting of SEQ ID NO: 143, said residues linked together by phosphorothioate linkages.

16. A composition comprising (i) a chimeric nucleobase oligomer of up to 30 nucleobases in length, said nucleobase oligomer comprising SEQ ID NO: 143, and (ii) a pharmaceutically acceptable excipient.

17. The composition of claim 16, further comprising a colloidal dispersion system.

18. A catalytic RNA molecule capable of cleaving XIAP, HIAP1, or HIAP2 mRNA, the binding arms of which contain at least eight consecutive nucleobases of SEQ ID NO: 143.

19. The catalytic RNA molecule of claim 18, wherein said RNA molecule is in a hammerhead motif.

20. The catalytic RNA molecule of claim 18, wherein said RNA molecule is in a hairpin, hepatitis delta virus, group 1 intron, VS RNA or RNAseP RNA motif.

21. An expression vector comprising a nucleic acid encoding a catalytic RNA molecule, the binding arms of which contain at least eight consecutive nucleobases of SEQ ID NO: 143, said nucleic acid positioned for expression in a mammalian cell.

22. A double-stranded RNA molecule comprising between 21 and 29 nucleobases, said RNA molecule comprising SEQ ID NO: 143.

23. A double-stranded RNA molecule comprising between 50 and 70 nucleobases, said RNA molecule comprising a first domain of between 21 and 29 nucleobases that comprise SEQ ID NO: 143 ; a second domain complementary to said first domain, and a loop domain situated between said first and said second domains.

24. An expression vector comprising a nucleic acid molecule encoding a double stranded RNA molecule comprising between 50 and 70 nucleobases, said RNA molecule comprising a first domain of between 21 and 29 nucleobases that comprise SEQ ID NO: 143; a second domain complementary to said first domain, and a loop domain situated between said first and said second domains, said nucleic acid positioned for expression in a mammalian cell.

Details for Patent 7,091,333

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Aegera Therapeutics, Inc. (Verdun, CA) 2022-03-27 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Aegera Therapeutics, Inc. (Verdun, CA) 2022-03-27 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Aegera Therapeutics, Inc. (Verdun, CA) 2022-03-27 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Colorcon
AstraZeneca
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.